LMR Partners LLP purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 101,082 shares of the medical equipment provider’s stock, valued at approximately $2,802,000.

A number of other large investors have also recently bought and sold shares of BSX. Bronfman E.L. Rothschild L.P. raised its stake in Boston Scientific Corporation by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 338 shares in the last quarter. Guardian Life Insurance Co. of America raised its stake in Boston Scientific Corporation by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 49 shares in the last quarter. Commerce Bank purchased a new stake in Boston Scientific Corporation during the first quarter worth approximately $207,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Boston Scientific Corporation during the first quarter worth approximately $215,000. Finally, Parametrica Management Ltd purchased a new stake in Boston Scientific Corporation during the second quarter worth approximately $219,000. Institutional investors own 91.62% of the company’s stock.

Boston Scientific Corporation (NYSE BSX) opened at 26.47 on Wednesday. The company has a 50 day moving average of $27.26 and a 200-day moving average of $26.12. The stock has a market cap of $36.32 billion, a P/E ratio of 47.35 and a beta of 1.09. Boston Scientific Corporation has a 12-month low of $19.67 and a 12-month high of $28.51.

Boston Scientific Corporation (NYSE:BSX) last issued its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.01. The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. Boston Scientific Corporation’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.27 earnings per share. Equities analysts forecast that Boston Scientific Corporation will post $1.26 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/16/101082-shares-in-boston-scientific-corporation-bsx-acquired-by-lmr-partners-llp.html.

A number of equities research analysts recently commented on the stock. Zacks Investment Research lowered shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. UBS AG reiterated a “buy” rating and set a $31.00 price target (up from $30.00) on shares of Boston Scientific Corporation in a report on Tuesday, August 1st. BidaskClub lowered shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. Finally, BMO Capital Markets restated a “buy” rating and issued a $30.00 price objective on shares of Boston Scientific Corporation in a report on Wednesday, June 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $30.06.

In related news, SVP David A. Pierce sold 13,562 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $28.00, for a total value of $379,736.00. Following the sale, the senior vice president now owns 33,701 shares in the company, valued at $943,628. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael P. Phalen sold 15,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $27.25, for a total value of $422,375.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 207,625 shares of company stock worth $5,686,383. 0.74% of the stock is owned by insiders.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.